KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Current Assets (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Current Assets data on record, last reported at $2.7 billion in Q3 2025.

  • For Q3 2025, Current Assets rose 1.38% year-over-year to $2.7 billion; the TTM value through Sep 2025 reached $2.7 billion, up 1.38%, while the annual FY2024 figure was $3.1 billion, 19.16% up from the prior year.
  • Current Assets reached $2.7 billion in Q3 2025 per SRPT's latest filing, up from $2.7 billion in the prior quarter.
  • Across five years, Current Assets topped out at $3.1 billion in Q4 2024 and bottomed at $2.2 billion in Q3 2021.
  • Average Current Assets over 5 years is $2.5 billion, with a median of $2.5 billion recorded in 2022.
  • Peak YoY movement for Current Assets: decreased 10.83% in 2021, then rose 20.16% in 2022.
  • A 5-year view of Current Assets shows it stood at $2.6 billion in 2021, then dropped by 1.78% to $2.6 billion in 2022, then grew by 0.84% to $2.6 billion in 2023, then rose by 19.16% to $3.1 billion in 2024, then dropped by 11.43% to $2.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $2.7 billion in Q3 2025, $2.7 billion in Q2 2025, and $2.4 billion in Q1 2025.